Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Prasugrel, Investigational Antiplatelet Agent by Daiichi Sankyo and Lilly

The results of the phase III trial showed that treatment with prasugrel was associated with a significant reduction in the composite primary efficacy endpoint as well as in MI, urgent target vessel revascularisation (TVR), and stent thrombosis.



  • The results of the phase III trial of Prasugrel

Go Top